SCHEMBL22015968

SCHEMBL22015968

CC(C)(C)OC(=O)N1CCN(c2ccc(Nc3ncc4cc(C#N)c(=O)n(C5CCCC5)c4n3)cc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 17/20 0.75
CCND1 P24385 17/20 0.75
CDK2 P24941 13/20 0.75
CCNA2 P20248 11/20 0.75
FGFR1 P11362 9/20 0.75
CDK6 Q00534 4/20 0.75
NUAK1 O60285 3/20 0.75
CCNE1 P24864 3/20 0.75
CCNT1 O60563 2/20 0.75
CDK9 P50750 2/20 0.75
PIK3CD O00329 1/20 0.75
PRKAB2 O43741 1/20 0.75
ABL1 P00519 1/20 0.75
FYN P06241 1/20 0.75
CDK1 P06493 1/20 0.75
CSF1R P07333 1/20 0.75
RET P07949 1/20 0.75
PDGFRB P09619 1/20 0.75
CCNB1 P14635 1/20 0.75
MARK3 P27448 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508788 0.91 CDK4 (0.61) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL22860140 0.90 CDK4 (0.60) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL29508832 0.90 CDK4 (0.62) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL29508870 0.90 CDK4 (0.60) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL22860109 0.90 CDK4 (0.62) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL29508813 0.90 CDK4 (0.61) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL22860292 0.89 CDK4 (0.59) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL29508857 0.89 CDK4 (0.59) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL22860687 0.89 CCND1 (0.58) CDK4CCND1CDK2CCNA2FGFR1
SCHEMBL29508816 0.89 CCND1 (0.58) CDK4CCND1CDK2CCNA2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002293-A1 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS ONCONOVA THERAPEUTICS, INC. (US) 2022-01-06 US disclosed
CN-112969463-A 8-cyclopentyl-7-oxo-2- (4-piperazin-1-yl-phenylamino) -7, 8-dihydro-pyrido [2,3-D ] pyrimidine-6-carbonitrile and its use in the treatment of proliferative diseases 安哥洛华治疗公司 2021-06-15 CN disclosed
WO-2020101638-A1 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS ONCONOVA THERAPEUTICS, INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002293-A1 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS DPYD, POLN, DCK CDK4 8/4885CCND1 211/4885CDK2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.